ISIS-TTRRx regulatory update

FDA granted Fast Track designation to Isis' ISIS-TTRRx to treat familial amyloid polyneuropathy. Isis plans to start a Phase II/III trial of the transthyretin (TTR) antisense inhibitor this month. IS...